Kalkine Media explores why IVERIC (ISEE) stock rose in pre-market hours

September 06, 2022 05:31 AM PDT | By Rupam Roy
 Kalkine Media explores why IVERIC (ISEE) stock rose in pre-market hours
Image source: © Pattanaphongphoto | Megapixl.com

Highlights:

  • The ISEE stock soared more than 47 per cent in the pre-market hours on Tuesday.
  • Iveric announced positive topline data for Zimura on September 6.
  • Iveric stock had an RSI of about 31.

The healthcare firm IVERIC bio, Inc. (NASDAQ:ISEE) gained notable traction in the market after it posted positive topline clinical trial data for its product. The ISEE stock grew more than 47 per cent in the pre-market trading hours on September 6.

Let's dive deep into the recent report of the firm about its clinical trial report before exploring its financials and stock performance.

Why is ISEE stock rising?

Iveric bio, a biotechnology firm that focuses on developing treatments for retinal diseases, unveiled positive topline results for GATHER2. GATHER2 is Iveric's second Phase 3 three trial of Zimura, which is a novel investigational complement C5 inhibitor. Zimura is mainly used to treat geographic atrophy (GA).

According to the company's announcement, GATHER2 had successfully shown positive results for its prespecified primary endpoint of the mean rate of growth in geographic atrophy treatment at 12 months with statistical significance and a favorable safety profile.

Meanwhile, the company said that there were no events of endophthalmitis or intraocular inflammation in GATHER2. Besides, there were no ischemic optic neuropathy events also witnessed through month 12 of the trial.

Iveric bio, Inc. (ISEE) latest quarter earnings highlightsSource: ©Kalkine Media®; © Canva Creative Studio via Canva.com

Fiscal 2022 second quarter financial highlights:

The investors may have lauded this positive topline data announcement by the firm while being optimistic about the company. Additionally, the company also said during its second-quarter earnings and operational release, that it expects a topline data for Zimura GATHER2 in September.

Talking about its financials, the Cranbury, New Jersey-based firm posted a total operating expense of US$ 49.75 million in Q2 FY22, compared to US$ 30.20 million in the year-ago quarter. The net loss of the US$ 1.62 billion market cap firm totaled US$ 49.26 million in the fiscal 2022 second quarter, against a loss of US$ 30.14 million in the same quarter of the preceding year.

Bottom line:

The price of the ISEE stock was up 47.46 per cent at 7:29 am ET on September 2 to trade at US$ 13.92. Its previous closing price was US$ 9.44 on September 2. Its trading volume was about 3.19 million at the time of writing.

However, despite the gains, investors should also evaluate other indicators before considering an investment in the equity market. For instance, the ISEE stock had an RSI of about 31, suggesting that the stock could be in a highly volatile condition.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next